Serum prorenin levels and diabetic retinopathy in type 2 diabetes: New method to measure serum level of prorenin using antibody activating direct kinetic assay

British Journal of Ophthalmology

Volumn 89, Issue 7, 2005, Pages 871-873

  Yokota, Harumasa ^a   Mori, F ^a   Kai, K ^a   Nagaoka, T ^a   Izumi, N ^a   Takahashi, A ^a   Hikichi, T ^a   Yoshida, A ^a   Suzuki, F ^b   Ishida, Y ^c  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Preveqol Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PRORENIN;

ADULT; AGED; ANTIBODY ACTIVATING DIRECT PRORENIN ASSAY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; EVALUATION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; TECHNIQUE;

ANTIBODIES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RENIN; TIME FACTORS;

EID: 21344434286     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.056580     Document Type: Article

References (38)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Mattock MB, Cronin N, Cavallo-Perin P, et al. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 2001;18:59-67.
3. Luetscher JA, Kraemer FB, Wilson DM, et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985;312:1412-17.
4. Franken AA, Derkx FH, Schalekamp MA, et al. Association of high plasma prorenin with diabetic retinopathy. J Hypertens Suppl 1988;6:S461-3.
5. Franken AA, Derkx FH, Blankestijn PJ, et al. Plasma prorenin as an early marker of microvascular disease in patients with diabetes mellitus. Diabete Metab 1992;18:137-43.
6. Allen TJ, Cooper ME, Gilbert RE, et al. Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996;50:902-7.
7. Deinum J, Ronn B, Mathiesen E, et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-10.
8. Chiarelli F, Pomilio M, De Luca FA, et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol 2001;16:116-20.
9. Kordonouri O, Wladimirowa A, Danne T. High total serum renin concentrations are associated with the development of background retinopathy in adolescents with type 1 diabetes. Diabetes Care 2000;23:1025-6.
10. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991;37:1811-19.
11. Cooper RM, Murray GE, Osmond DH. Trypsin-induced activation of renin precursor in plasma of normal and anephric man. Circ Res 1977;40:1171-9.
12. Derkx FH, de Bruin RJ, van Gool JM, et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996;42:1051-63.
13. Suzuki F, Hatano Y, Nakagawa T, et al. Non-proteolytic activation of human prorenin by anti-prorenin prosegment (pf#1: 1P-15P) antiserum. Biosci Biotechnol Biochem 1999;63:550-4.
14. Kawazu S, Minagawa S, Yazawa M, et al. Sex difference and possible relationship to microvascular complications of serum prorenin levels in type 2 diabetic patients, measured by a novel antibody-activating direct enzyme kinetic assay. Journal of Diabetes and Its Complications 2004;18:275-81.
15. Makimattila S, Summanen P, Matinlauri I, et al. Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM. Br J Ophthalmol 1998;82:939-44.
16. Sealey JE, Glorioso N, Itskovitz J, et al. Prorenin as a reproductive hormone. New form of the renin system. Am J Med 1986;81:1041-6.
17. Ubeda M, Hernandez I, Fenoy F, et al. Vascular and adrenal reninlike activity in chronically diabetic rats. Hypertension 1988;11:339-43.
18. Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35.
19. Chaturvedi N, Sjoelie AK, Porta M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001;24:284-9.
20. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis or non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116:297-303.
21. Derkx FH, Schalekamp MA. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988;10:1213-25.
22. Drury PL, Bodansky HJ, Oddie CJ, et al. Increased plasma renin activity in type 1 diabetes with microvascular disease. Clin Endocrinol 1982;16:453-61.
23. Moravski CJ, Skinner SL, Stubbs AJ, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 2003;162:151-60.
24. Funatsu H, Yamashita H. Pathogenesis of diabetic retinopathy and the renin-angiotensin system. Ophthalmic Physiol Opt 2003;23:495-501.
25. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002;16(Suppl 3):S42-6.
26. Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 2003;278:22217-22.
27. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.
28. Prescoft G, Silversides DW, Reudelhuber TL. Tissue activity of circulating prorenin. Am J Hypertens 2002;15:280-5.
29. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vasc Res 2001;38:527-35.
30. Sarlos S, Rizkalla B, Moravski CJ, et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003;163:879-87.
31. Otani A, Takagi H, Suzuma K, et al. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619-28.
32. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099-104.
33. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Miner Electrolyte Metab 1998;24:400-5.
34. Otani A, Takagi H, Oh H, et al. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001;50:867-75.
35. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274:15732-9.
36. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2003;44:393-402.
37. Umeda N, Ozaki H, Hayashi H, et al. Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalmic Res 2003;35:217-23.
38. Oshima Y, Deering T, Oshima S, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 2004;199:412-17.